IDEXX Laboratories, Inc. $IDXX Stock Position Lowered by Sterling Capital Management LLC

Sterling Capital Management LLC decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 35.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,293 shares of the company’s stock after selling 1,779 shares during the quarter. Sterling Capital Management LLC’s holdings in IDEXX Laboratories were worth $1,850,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Beacon Investment Advisory Services Inc. raised its holdings in IDEXX Laboratories by 11.9% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after buying an additional 6,710 shares during the period. Nordea Investment Management AB boosted its holdings in shares of IDEXX Laboratories by 114.1% in the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after buying an additional 8,845 shares during the period. Procyon Advisors LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter worth about $1,966,000. Diversified Trust Co. boosted its holdings in shares of IDEXX Laboratories by 223.5% in the fourth quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock worth $2,841,000 after buying an additional 2,901 shares during the period. Finally, Mirabella Financial Services LLP increased its position in shares of IDEXX Laboratories by 156.2% in the third quarter. Mirabella Financial Services LLP now owns 4,401 shares of the company’s stock worth $2,806,000 after acquiring an additional 2,683 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

IDXX stock opened at $535.93 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The stock has a market cap of $42.27 billion, a P/E ratio of 39.46, a P/E/G ratio of 3.02 and a beta of 1.56. The firm has a 50 day simple moving average of $558.11 and a 200 day simple moving average of $612.98. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the firm posted $2.91 earnings per share. The firm’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on IDXX shares. UBS Group reduced their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Citigroup initiated coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price for the company. Finally, Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.